Literature DB >> 9278198

The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis.

M M van Miert1, N B Eastwood, A H Boyd, C J Parker, J M Hunter.   

Abstract

AIMS: To determine the effects of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of rocuronium bromide.
METHODS: We studied 21 healthy patients and 17 patients with mild or moderate cirrhosis (Child-Pugh Class A and B). Patients were premedicated with diazepam orally; anaesthesia was induced with fentanyl and thiopentone, and maintained with isoflurane 0.6% (end-tidal) and nitrous oxide 66% in oxygen. The compound action potential of the adductor pollicis muscle in response to supramaximal stimulation of the ulnar nerve was recorded using the train-of-four (TOF) twitch technique. A bolus dose of rocuronium 0.6 mg kg(-1) was then given. Venous blood samples were taken for up to 8 h, and plasma rocuronium concentrations determined by h.p.l.c.
RESULTS: The time to onset of neuromuscular block and maximal block achieved did not differ between the two groups. The mean (s.d.) recovery times were prolonged in the cirrhotic compared with the healthy group: 25% recovery T1:T0, 53.7 (18.1) vs 42.3 (14.2) min; 50% recovery T1:T0, 73.9 (33.9) vs 52.6 (19.8) min; 75% recovery T1:T0, 84.2 (24.5) vs 66.8 (27.2) min (all P<0.05); recovery of T4:T1 to 70%, 114.9 (31.7) vs 76.1 (28.8) min (P<0.01). A pharmacokinetic and pharmacodynamic model was fitted to the data for each patient. Three compartments were used to model the pharmacokinetic data; an effect compartment was added to model the pharmacodynamic data. Plasma clearance was significantly reduced in the cirrhotic group (2.66 (0.60) vs 3.70 (1.03) ml kg(-1) min (-1); P<0.005). The central (V1) and steady state volumes of distribution (V(ss)) did not differ significantly between the groups. The slow redistribution (t1/2,lambda1) and elimination (t1/2,z) half-lives were both significantly prolonged in cirrhosis (28.3 (12.1) vs 16.8 (4.6) min, P < 0.005; and 143 (80) vs 92 (40) min, P < 0.05 respectively). The exit rate constant for the effect compartment k(eo) was significantly increased in the cirrhotic group (0.25 (0.18) vs 0.16 (0.06) min(-1); P < 0.05), but cirrhosis had no significant effect on the parameters of the concentration-effect relationship Cp(ss)(50) and gamma.
CONCLUSIONS: Hepatic elimination is an important pathway in the clearance of rocuronium, and delayed disposition causes the effect to be prolonged.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278198      PMCID: PMC2042830          DOI: 10.1046/j.1365-2125.1997.00653.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.

Authors:  A C C Costa; E B Coelho; V L Lanchote; B V Correia; J T Abumansur; G R Lauretti; N V de Moraes
Journal:  Eur J Clin Pharmacol       Date:  2017-04-14       Impact factor: 2.953

Review 3.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  [Perioperative anesthesia management of extended partial liver resection. Pathophysiology of hepatic diseases and functional signs of hepatic failure].

Authors:  S Herz; G Puhl; C Spies; D Jörres; P Neuhaus; C von Heymann
Journal:  Anaesthesist       Date:  2011-02       Impact factor: 1.041

5.  Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery.

Authors:  Juan Fernández-Candil; Pedro L Gambús; Iñaki F Trocóniz; Ricard Valero; Enrique Carrero; Lorea Bueno; Neus Fábregas
Journal:  Eur J Clin Pharmacol       Date:  2008-06-03       Impact factor: 2.953

6.  Effects on Intubating Conditions of Pretreatment with Remifentanil before Administration of Cisatracurium.

Authors:  Hye Jin Jeong; Seong Heon Lee; Hwi Jin Kim; Sang Hyun Kwak
Journal:  Chonnam Med J       Date:  2012-08-24

7.  Increased Renal Clearance of Rocuronium Compensates for Chronic Loss of Bile Excretion, via upregulation of Oatp2.

Authors:  Long Wang; Mai-Tao Zhou; Cai-Yang Chen; Wen Yin; Da-Xiang Wen; Chi-Wai Cheung; Li-Qun Yang; Wei-Feng Yu
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

8.  Anesthesiologist's satisfaction using between cisatracurium and rocuronium for the intubation in the anesthesia induced by remifentanil and propofol.

Authors:  Hyunjung Lee; Sinho Jeong; Cheolhun Choi; Hyejin Jeong; Seongheon Lee; Seongwook Jeong
Journal:  Korean J Anesthesiol       Date:  2013-01-21

9.  Influence of obstructive jaundice on pharmacodynamics of rocuronium.

Authors:  Zhen-Meng Wang; Peng Zhang; Mi-Jia Lin; Bo Tan; Hai-Bo Qiu; Wei-Feng Yu
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  Effect of pneumoperitoneum on the recovery from intense neuromuscular blockade by rocuronium in healthy patients undergoing laparoscopic surgery.

Authors:  Hong Soon Kim; Dong Chul Lee; Mi Geum Lee; Woon Rak Son; Yong Beom Kim
Journal:  Korean J Anesthesiol       Date:  2014-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.